The lowered full-year revenue guidance is the dominant signal, likely outweighing the Q2 beat. Traders should watch for further commentary on the guidance revision during the earnings call and monitor prescription trends in Q3 to assess if the slowdown is temporary or structural.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $9.03entry
- T+1 · 4mo ago −3.10%α −3.81% · $8.75
- T+5 · 3mo ago −7.09%α −10.71% · $8.39
- T+20 · 3mo ago −1.00%α −4.96% · $8.94
- T+60 · 25d ago −36.43%α −38.90% · $5.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by strong VOQUEZNA prescription growth. However, GAAP EPS was -$0.21, below the consensus estimate of -$0.15, and the company lowered its full-year 2026 revenue guidance to $310-325M from $320-345M, signaling a more cautious outlook despite the strong quarter. The stock is likely to trade down on the guidance cut and EPS miss, partially offset by the revenue beat and progress toward profitability.
Key Financial Metrics
Key Facts
- Q2 2026 net revenue of $74.3M, up 88% YoY and 27% QoQ, beating consensus of $72.7M.
- GAAP EPS of -$0.21 missed consensus of -$0.15, a 40% miss.
- Full-year 2026 revenue guidance lowered to $310-325M from $320-345M.
- Non-GAAP adjusted net loss was just $0.1M, nearing operating profitability.
- Approximately 325,000 total VOQUEZNA prescriptions filled in Q2, up 88% YoY.
- Cash and equivalents of $182.5M as of June 30, 2026, up from $129.97M at year-end 2025.
Financial Impact
Revenue beat by ~2.2% ($74.3M vs $72.7M consensus), but EPS missed by 40% (-$0.21 vs -$0.15 consensus). Full-year revenue guidance cut by $10-20M at the midpoint.
Risk Factors
- Lowered full-year revenue guidance suggests slowing growth trajectory in H2 2026.
- EPS miss indicates higher-than-expected costs or lower margins, despite revenue growth.
- Dependence on VOQUEZNA for nearly all revenue; pipeline catalysts (Phase 3 NERD, Phase 2 EoE) are not expected until Q4 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335890 |
Track record
16 reports on PHAT
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.37% at T+5 after the Oct 23, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $6.28 Now $5.88 −6.37% settles Nov 18
- Nov 2, 202614d ago SC 13D/A Neutral 3/10 Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
- Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
- Jul 30, 202615w ago 8-K Mixed 5/10 No price data
- Jul 30, 202615w ago Press Release Bearish 6/10 Viewing Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers